96 results match your criteria vincristine acts

Punicalagin and ellagic acid containing fruit rind extract prevents vincristine-induced neuropathic pain in rats: an and evidence of GABAergic action and cytokine inhibition.

Nutr Neurosci 2021 Aug 9:1-18. Epub 2021 Aug 9.

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

We aimed to investigate the protective potential of Punica granatum L. fruit rind extract (PFE) containing punicalagin (10.3% W/W), ellagic acid (EA) (2. Read More

View Article and Full-Text PDF

Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment.

Int J Mol Sci 2021 Apr 16;22(8). Epub 2021 Apr 16.

Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, 00168 Rome, Italy.

Vincristine-induced peripheral neurotoxicity (VIPN) is a very common side effect of vincristine chemotherapy among pediatric patients with cancer. Neuropathy may be sensory, motor and/or autonomic, with consequent reduction, delay or discontinuation of vincristine-chemotherapy, but also pain, disability, reduced quality of life of patients and an increase in medical costs. Vincristine acts out its antineoplastic function by altering the normal assembly and disassembly of microtubules, with their consequent mitosis block and death. Read More

View Article and Full-Text PDF

Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report.

J Cancer Res Ther 2020 Sep;16(5):1177-1181

Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Desmoplastic small round cell tumor (DSRCT) is a type of soft-tissue sarcoma with poor prognosis. Current treatments include multidisciplinary treatment options such as surgery, chemotherapy, and radiotherapy. Apatinib is an oral, small-molecule, anti-tumor, angiogenesis-targeted drug, which acts mainly on the intracellular binding site of vascular endothelial growth factor receptor-2. Read More

View Article and Full-Text PDF
September 2020

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.

Ann Oncol 2019 11 24;30 Suppl 8:viii31-viii35. Epub 2019 Dec 24.

Radiologic Institute, Center for Pediatric, Adolescent and Women's Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.

Background: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib.

Patient And Methods: A male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Read More

View Article and Full-Text PDF
November 2019

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.

Ann Oncol 2019 11;30(Suppl_8):viii31-viii35

Radiologic Institute, Center for Pediatric, Adolescent and Women's Medicine, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart.

Background: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib.

Patient And Methods: A male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Read More

View Article and Full-Text PDF
November 2019

Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway.

Phytomedicine 2019 Feb 17;54:1-8. Epub 2018 Sep 17.

Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua 500, Taiwan.

Background: Oral cancers are one of the most aggressive malignancies, with high mortality rates globally. Patients with these cancers are treated using combination therapies including surgery, chemotherapy, and radiotherapy.

Hypothesis/purpose: Traditional Chinese medicines and other herbal medicines have been used to treat various diseases in Asia. Read More

View Article and Full-Text PDF
February 2019

Metal-free salan-type compound induces apoptosis and overcomes multidrug resistance in leukemic and lymphoma cells in vitro.

J Cancer Res Clin Oncol 2018 Apr 27;144(4):685-695. Epub 2018 Jan 27.

Department of Pediatric Hematology/Oncology, Children's Hospital Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.

Purpose: We report on our preclinical findings of a simple salicylic diamine compound (THG 1213) which has yielded exceptional results as a potential chemotherapeutic drug. THG 1213 is an easy to synthesize chiral and metal-free salan compound.

Methods: THG 1213 was tested on several leukemia, lymphoma and solid tumor cell lines in vitro. Read More

View Article and Full-Text PDF

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Blood Adv 2018 01 27;2(1):1-9. Epub 2017 Dec 27.

Medizinische Klinik V and.

We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Read More

View Article and Full-Text PDF
January 2018

Targeting mitochondrial respiration selectively sensitizes pediatric acute lymphoblastic leukemia cell lines and patient samples to standard chemotherapy.

Am J Cancer Res 2017 1;7(12):2395-2405. Epub 2017 Dec 1.

Department of Pediatrics, Zhongnan Hospital of Wuhan University, Wuhan UniversityWuhan 430071, China.

The clinical management of pediatric acute lymphoblastic leukemia (ALL) is still changeling and identification of agents that can sensitize standard chemotherapy is needed for its better management. In this work, we demonstrate that tigecycline, a FDA-approved antibiotic, is an attractive candidate for ALL treatment. Tigecycline inhibits growth and induces apoptosis of multiple ALL cell lines. Read More

View Article and Full-Text PDF
December 2017

WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects.

Oncotarget 2017 Sep 9;8(42):71782-71796. Epub 2017 May 9.

Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.

Cancer drug researchers have been seeking microtubule-inhibiting agents (MIAs) with higher bioactivity and lower toxicity than currently marketed drugs. WX-132-18B, a novel structural compound synthesized at our institute, specifically bound to the colchicine-binding site on tubulin rather than the vinblastine site, and concentration-dependently reduced microtubule content via depolymerization. It exhibited the same cellular phenotypic profiles as the classic MIAs (colchicine, vincristine, and taxol), including inducing cell cycle arrest at the G2/M phase, triggering tumor cell apoptosis, promoting nuclear membrane permeability, reducing mitochondrial membrane potential, and disrupting the redox system balance. Read More

View Article and Full-Text PDF
September 2017

Synergistic Interaction Between Dexmedetomidine and Ulinastatin Against Vincristine-Induced Neuropathic Pain in Rats.

J Pain 2017 11 8;18(11):1354-1364. Epub 2017 Jul 8.

Department of Anesthesiology, State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address:

Antimicrotubulin chemotherapeutic agents such as vincristine (VCR), often induce peripheral neuropathic pain. It is usually permanent and seriously harmful to cancer patients' quality of life and can result in the hampering of clinical treatments. Currently, there is no definitive therapy, and many of the drugs approved for the treatment of other neuropathic pain have shown little or no analgesic effect. Read More

View Article and Full-Text PDF
November 2017

The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

Cancer Lett 2017 09 7;403:74-85. Epub 2017 Jun 7.

Cancer Epigenetics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Electronic address:

Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are associated with high-risk and relapsing neuroblastoma. As both ALK and RAS signal through the MEK/ERK pathway, we sought to evaluate two previously reported inhibitors of ETS-related transcription factors, which are transcriptional mediators of the Ras-MEK/ERK pathway in other cancers. Read More

View Article and Full-Text PDF
September 2017

Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance.

Int J Oncol 2017 Jul 17;51(1):257-268. Epub 2017 May 17.

National Administration of Traditional Chinese Medicine Key Laboratory of Chinese Medicine Digital Quality Evaluation Technology, College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China.

The overexpression of ATP-binding cassette (ABC) transporters is the main cause of cancer multidrug resistance (MDR), which leads to chemotherapy failure. Uncaria alkaloids are the major active components isolated from uncaria, which is a common Chinese herbal medicine. In this study, the MDR-reversal activities of uncaria alkaloids, including rhynchophylline, isorhynchophylline, corynoxeine, isocorynoxeine (Icory), hirsutine and hirsuteine, were screened; they all exhibited potent reversal efficacy when combined with doxorubicin. Read More

View Article and Full-Text PDF

A differentially regulated AP2/ERF transcription factor gene cluster acts downstream of a MAP kinase cascade to modulate terpenoid indole alkaloid biosynthesis in Catharanthus roseus.

New Phytol 2017 Feb 1;213(3):1107-1123. Epub 2016 Nov 1.

Department of Plant and Soil Sciences and Kentucky Tobacco Research Development Center, University of Kentucky, 1401 University Drive, Lexington, KY, 40546, USA.

Catharanthus roseus produces bioactive terpenoid indole alkaloids (TIAs), including the chemotherapeutics, vincristine and vinblastine. Transcriptional regulation of TIA biosynthesis is not fully understood. The jasmonic acid (JA)-responsive AP2/ERF transcription factor (TF), ORCA3, and its regulator, CrMYC2, play key roles in TIA biosynthesis. Read More

View Article and Full-Text PDF
February 2017

The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

Invest New Drugs 2017 02 26;35(1):26-36. Epub 2016 Oct 26.

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes 3900, 14048-900, Ribeirão Preto, SP, Brazil.

Medulloblastoma (MB) is the most common solid tumor among pediatric patients and corresponds to 20 % of all pediatric intracranial tumors in this age group. Its treatment currently involves significant side effects. Epigenetic changes such as DNA methylation may contribute to its development and progression. Read More

View Article and Full-Text PDF
February 2017

Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Onco Targets Ther 2016 23;9:3799-805. Epub 2016 Jun 23.

Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Objectives: The objective of this study was to investigate the expression level of CD40 and its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Design And Methods: The immunohistochemical expressions of CD40 in 186 well-characterized DLBCL patients were evaluated by tissue microarrays, thereby revealing the relationship of the molecule CD40 with known tumor, patient-related variables, and survival rates.

Results: The results showed that CD40 expressions were not statistically different between the germinal center B-cell-like (GCB) type and the non-GCB type. Read More

View Article and Full-Text PDF

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.

Cancer Chemother Pharmacol 2016 Apr 13;77(4):685-92. Epub 2016 Feb 13.

Great Ormond Street Hospital, London, WC1N 3JH, UK.

Purpose: Selection of the most appropriate chemotherapy dosing regimens for neonates treated within the first weeks of life represents a significant clinical dilemma. Due to a lack of information relating to the clinical pharmacology of anticancer drugs in these challenging patients, current dosing guidelines are based on limited scientific rationale. In the current study, we investigate the utilisation of therapeutic drug monitoring approaches in neonates with localised hepatoblastoma, Wilms' tumour and stage 4S neuroblastoma, being treated with widely used anticancer drugs. Read More

View Article and Full-Text PDF

Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.

Oncotarget 2015 Dec;6(39):41522-34

Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany.

We explored the potential of Smac mimetics, which antagonize Inhibitor of Apoptosis (IAP) proteins, for chemosensitization of neuroblastoma (NB). Here, we report that Smac mimetics, e.g. Read More

View Article and Full-Text PDF
December 2015

Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes.

Yuzhen Xu Liyan Qiu

Int J Nanomedicine 2015 29;10:4225-37. Epub 2015 Jun 29.

Ministry of Education Key Laboratory of Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, People's Republic of China.

The use of vincristine (VCR) to treat cancer has been limited by its dose-dependent toxicity and development of drug resistance after repeated administrations. In this study, we investigated the mechanism by which quinine hydrochloride (QN) acts as a sensitizer for VCR. Our experiments used three kinds of multidrug-resistant cancer cells and demonstrated that QN worked by inducing intracellular depletion of adenosine triphosphate, increasing adenosine triphosphatase activity, and decreasing P-glycoprotein expression. Read More

View Article and Full-Text PDF

P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Cancer Med 2015 Oct 8;4(10):1494-504. Epub 2015 Jul 8.

Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Epstein-Barr virus-positive T-cell lymphoproliferative diseases (EBV-T-LPDs) are rare lymphomas with poor prognosis. Although chemotherapeutic strategies such as CHOP have been often selected, they have exhibited only limited efficacy. To clarify the mechanism of chemoresistance, we examined P-glycoprotein (P-gp) expression. Read More

View Article and Full-Text PDF
October 2015

The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.

Int J Oncol 2015 Jul 11;47(1):343-52. Epub 2015 May 11.

Department of Biochemistry, Faculty of Science, Charles University, 128 40 Prague 2, Czech Republic.

High-risk neuroblastoma remains one of the most important therapeutic challenges for pediatric oncologists. New agents or regimens are urgently needed to improve the treatment outcome of this fatal tumor. We examined the effect of histone deacetylase (HDAC) inhibitors in a combination with other chemotherapeutics on a high-risk neuroblastoma UKF-NB-4 cell line. Read More

View Article and Full-Text PDF

Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers.

PLoS One 2015 31;10(3):e0120487. Epub 2015 Mar 31.

Department of Physiology, University of Lausanne, Lausanne, Switzerland.

Although current anti-cancer protocols are reasonably effective, treatment-associated long-term side effects, induced by lack of specificity of the anti-cancer procedures, remain a challenging problem in pediatric oncology. TAT-RasGAP317-326 is a RasGAP-derived cell-permeable peptide that acts as a sensitizer to various anti-cancer treatments in adult tumor cells. In the present study, we assessed the effect of TAT-RasGAP317-326 in several childhood cancer cell lines. Read More

View Article and Full-Text PDF

Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.

Fundam Clin Pharmacol 2015 Feb 3;29(1):62-71. Epub 2014 Dec 3.

Laboratoire de Toxicologie du Médicament, Institut des Biomolécules Max Mousseron (UMR5247), UFR des Sciences Pharmaceutiques et Biologiques, Université Montpellier I, 15 avenue Charles Flahault, BP14491, Montpellier, 34093, France.

On account of its extreme intrinsic resistance to apoptosis and of its strong ability to become chemoresistant after a primary response to drugs, malignant melanoma (MM) is still a therapeutic challenge. We previously showed that glutathione S-transferase mu 1 (GSTM1) acts in synergy with multidrug resistance protein 1 (MRP1) to protect GSTM1-transfected human CAL1 melanoma cells from toxic effects of vincristine (VCR). Herein, we investigated the role of these proteins in the acquired resistance of CAL1 cells to vinca alkaloids (VAs). Read More

View Article and Full-Text PDF
February 2015

DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis.

Nat Cell Biol 2014 Aug 27;16(8):812-20. Epub 2014 Jul 27.

Institute of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190 CH-8057 Zurich, Switzerland.

Microtubule-targeting chemotherapeutics induce apoptosis in cancer cells by promoting the phosphorylation and degradation of the anti-apoptotic BCL-2 family member MCL1. The signalling cascade linking microtubule disruption to MCL1 degradation remains however to be defined. Here, we establish an in vivo screening strategy in Caenorhabditis elegans to uncover genes involved in chemotherapy-induced apoptosis. Read More

View Article and Full-Text PDF

Sarm1-mediated axon degeneration requires both SAM and TIR interactions.

J Neurosci 2013 Aug;33(33):13569-80

Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Axon degeneration is an evolutionarily conserved pathway that eliminates damaged or unneeded axons. Manipulation of this poorly understood pathway may allow treatment of a wide range of neurological disorders. In an RNAi-based screen performed in cultured mouse DRG neurons, we observed strong suppression of injury-induced axon degeneration upon knockdown of Sarm1 [SARM (sterile α-motif-containing and armadillo-motif containing protein)]. Read More

View Article and Full-Text PDF

Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos.

BMC Biol 2013 Jun 17;11:69. Epub 2013 Jun 17.

Department of Bioanalytical Ecotoxicology, UFZ - Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany.

Background: In mammals, ABCB1 constitutes a cellular "first line of defense" against a wide array of chemicals and drugs conferring cellular multidrug or multixenobiotic resistance (MDR/MXR). We tested the hypothesis that an ABCB1 ortholog serves as protection for the sensitive developmental processes in zebrafish embryos against adverse compounds dissolved in the water.

Results: Indication for ABCB1-type efflux counteracting the accumulation of chemicals in zebrafish embryos comes from experiments with fluorescent and toxic transporter substrates and inhibitors. Read More

View Article and Full-Text PDF

Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.

Oncol Rep 2013 Aug 5;30(2):773-82. Epub 2013 Jun 5.

Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, PR China.

The phosphatidylinositol 3‑kinase (PI3K)/Akt signaling pathway plays a crucial role in tumorigenesis and tumor progression by promoting cell proliferation and inhibiting apoptosis, a process closely associated with multidrug resistance (MDR) of tumors. LY294002 is a commonly used pharmacological inhibitor that acts at the ATP‑binding site of the PI3K enzyme, selectively inhibiting the PI3K/Akt pathway. In the present study, we evaluated the effect of LY294002 on the chemosensitivity of gastric cancer cells to vincristine (VCR) in vitro and in vivo and investigated the possible underlying cellular mechanisms. Read More

View Article and Full-Text PDF

Effects of spindle poisons in peripheral human lymphocytes by the in vitro cytokinesis-block micronucleus assay.

Mutagenesis 2012 Nov 5;27(6):749-58. Epub 2012 Sep 5.

Dipartimento di Biologia (Unità di Genetica, Mutagenesi e Epidemiologia Ambientale), University of Pisa, via Derna 1, 56100 Pisa, Italy.

The search for micronuclei (MN) in binucleated cells is not always the best choice to recognize microtubule-perturbing agents, as they give rise to (micronucleated) mononucleated cells, mainly via mitotic slippage. We therefore treated peripheral lymphocytes with vincristine (VCR), nocodazole (NOC) and colcemid (COL): (i) to quantify the formation of MN in mononucleated cells and the occurrence of abnormal mitoses (c-anaphases, endoreduplicated or tetraploid metaphases); (ii) to investigate the role of cytokinesis inhibition in determining or modulating the cytogenetic effects induced by the spindle poisons (we used either cytochalasin B (cyt B) or latrunculin A, a cytokinesis inhibitor that acts differently as compared with cyt B); (iii) to assess the ploidy of cells bearing MN by fluorescence in situ hybridisation (FISH) analysis; and (iv) to evaluate the levels of the mitotic arrest deficient (MAD2) protein, that blocks the cell at the metaphase-anaphase transition, by immunoblotting. We observed the induction of numerous abnormal mitoses and tetraploid interphase nuclei, as well as of MN in mononucleated cells, a high percentage of which had a diploid complement. Read More

View Article and Full-Text PDF
November 2012

Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro.

BMC Complement Altern Med 2012 Jul 11;12:94. Epub 2012 Jul 11.

Clinical Pharmacy and Pharmacology Research Institute, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Background: Astragalus polysaccharides (APS) are active constituents of Astragalus membranaceus. They have been widely studied, especially with respect to their immunopotentiating properties, their ability to counteract the side effects of chemotherapeutic drugs, and their anticancer properties. However, the mechanism by which APS inhibit cancer and the issue of whether that mechanism involves the reversal of multidrug resistance (MDR) is not completely clear. Read More

View Article and Full-Text PDF

HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Cancer Res 2012 Aug 3;72(16):4204-13. Epub 2012 Jul 3.

Experimental Therapeutics, Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612, USA.

Transmembrane drug export mediated by the ATP-binding cassette (ABC) transporter P-glycoprotein contributes to clinical resistance to antineoplastics. In this study, we identified the substituted quinoline HG-829 as a novel, noncompetitive, and potent P-glycoprotein inhibitor that overcomes in vitro and in vivo drug resistance. We found that nontoxic concentrations of HG-829 restored sensitivity to P-glycoprotein oncolytic substrates. Read More

View Article and Full-Text PDF